Skip to main content
Premium Trial:

Request an Annual Quote

GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana

NEW YORK — GeninCode said on Monday that it has signed an agreement to commercialize its portfolio of polygenic cardiovascular disease products in the US with commercial services provider Eversana Life Sciences.

UK-based GeninCode offers a range of tests that combine genetic and clinical data to assess individuals for CVD risk including Cardio inCode for heart attack and other CVD-related conditions, Lipid inCode for familial hypercholesterolemia, and Sudd inCode for sudden cardiac death.

Under the terms of their deal, Milwaukee-based Eversana will launch GeninCode's products, beginning with Cardio inCode, using its complete commercialization offering, which includes clinical and commercial field teams, medical science liaisons, channel management, health economics, and outcomes research and compliance.

Financial and other terms were not disclosed.

"Eversana [provides] proven launch and commercialization expertise to support our market access and will help accelerate our speed to market," GeninCode CEO Matthew Walls said in a statement.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.